<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01235468</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-10-7959-AN-CTIL</org_study_id>
    <nct_id>NCT01235468</nct_id>
  </id_info>
  <brief_title>Allogenic Transplantation of Ex-vivo Expanded Cord Blood (CB)</brief_title>
  <official_title>Allogenic Transplantation of Ex-vivo Expanded CB Progenitors for Haematological Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <authority>Israel: Israeli Health Ministry Pharmaceutical Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety profile and tolerability of infusion of cord
      blood cells expanded in the lab and to evaluated whether through the infusion of expanded
      cells it is possible to expedite engraftment time after transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stem cell transplantation is a curative approach for patients with hematological
      malignancies. Umbilical cord blood is a source of stem cells for transplantation in patients
      with no related donor. However, in adults, the number of stem cells in a single unit, may be
      too low to allow engraftment, and the time to engraftment may be prolonged, increasing the
      risks of the transplant. In this study, we expand part of the cord blood unit, in the lab,
      trying to increase unit size, such that it would be suitable for adults, and would allow
      safe engraftment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients with adverse events during infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>engraftment</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time to engraftment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>treatment-related toxicity</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Type and severity of adverse events after transplantation using the NCI CTC scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GVHD</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients with acute and chronic GVHD after transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological reconstruction</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>immunological reconstruction after transplantation measured by lymphocyte number and function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>rate of disease recurrence</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Umbilical Cord Blood</condition>
  <condition>Stem Cell Transplantation</condition>
  <condition>Hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>CB expnasion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ex-vivo expansion of cord blood for transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ex vivo expansion</intervention_name>
    <description>ex-vivo expansion of cord blood for transplantation</description>
    <arm_group_label>CB expnasion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  hematological malignancy

          -  standard indication for allogeneic transplantation

          -  expected survival time over 12 weeks

          -  no related or unrelated donor

          -  availability of a cord blood unit of compatible placental blood cryopreserved in at
             least 2 different bags; one of the two units should have a cellular content at least
             equal to the minimum dose of 2 x 107 nucleated cells per kilogram of body weight

        Exclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status &gt;2

          -  Prior allogeneic transplantation

          -  Pregnant or nursing women

          -  Positive serology for hepatitis B or C

          -  HIV positive

          -  Left ventricular ejection fraction &lt; 50%

          -  DLCO &lt; 50%

          -  Psychiatric, addictive, or any disorder/disease which compromises ability to give
             informed consent for participation in this study

          -  Treatment with other investigational drugs within 4 weeks of enrolling in this
             protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnon Nagler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chaim Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arnon Nagler, MD</last_name>
    <phone>972 3 530 5830</phone>
    <email>a.nagler@sheba.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Avichai Shimoni, MD</last_name>
    <phone>972 3 530 5303</phone>
    <email>ashimoni@sheba.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnon Nagler, MD</last_name>
      <phone>972 3 530 5830</phone>
      <email>a.nagler@sheba.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Avichai Shimoni</last_name>
      <phone>972 3 530 5303</phone>
      <email>ashimoni@sheba.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Arnon Nagler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosaria Giordano, MD</last_name>
      <phone>39 02 5503 4053</phone>
    </contact>
    <investigator>
      <last_name>Rosaria Giordano, mMD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 23, 2011</lastchanged_date>
  <firstreceived_date>November 2, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Arnon Nagler, MD</name_title>
    <organization>Chaim Sheba Medical Center</organization>
  </responsible_party>
  <keyword>umbilical cord blood</keyword>
  <keyword>ex vivo expansion</keyword>
  <keyword>engraftment</keyword>
  <keyword>GVHD</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
</clinical_study>
